Reports Q1 revenue $2.9B vs. $208B last year. “During the quarter we installed our first pre-clinical trial site demonstrating our ability to successfully ship, install, train and run the Accelerate Wave system with Gram-Negative Positive Blood Culture samples in a clinical microbiology lab,” commented Jack Phillips, CEO. “We continue to target starting our clinical trial towards the end of the second quarter. In parallel to the clinical trial work, we are developing our Gram Positive PBC menu. We continue to present the Accelerate Wave to our current base of loyal customers and secure long-term rapid susceptibility testing contracts. The interest in Wave remains very high due to its differentiated and highly valued features”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXDX:
- Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results
- Accelerate Diagnostics price target lowered to $1 from $2 at Craig-Hallum
- Stockholders Beware: Accelerate Diagnostics’ Surge in Authorized Shares Signals Potential Dilution Risk
- Accelerate Diagnostics reports Q4 EPS (89c), consensus (75c)
- Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
Questions or Comments about the article? Write to editor@tipranks.com